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The discovery of a potent mitogen for insulin-producing pancreatic b cells, optimistically termed ‘‘betatro-
phin,’’ excited researchers and laypeople alike, promising a new therapeutic approach to diabetes. A recent
‘‘Matters Arising’’ report by Gusarova and colleagues (2014) places serious doubts on whether ‘‘betatrophin’’
plays any major role in b cell replication.A 2013 report published in Cell identified
the circulating protein angiopoietin-like 8
(ANGPTL8, also known as ‘‘lipasin,’’
‘‘RIFL,’’ or ‘‘Gm6484’’), produced primar-
ily by liver and adipose tissue, as a novel
hormone promoting b cell proliferation—
renamed ‘‘betatrophin’’ by the authors—
and raised high hopes in the scientific
and lay community alike that an entirely
new treatment option for diabetes might
be on the horizon (Yi et al., 2013). In fact,
given the impressive publicity received
by the study in the lay press and social
media, thousands of patients approached
their physicians with questions about the
new ‘‘wonder drug,’’ and philanthropists
rescinded their support for diabetes
research centers. Unfortunately, several
recent articles now show that the celebra-
tion was premature, and that ANGPTL8,
or ‘‘betatrophin,’’ plays little to no role as
a b cell mitogen (Gusarova et al., 2014;
Wang et al., 2013).
How was ANGPTL8 implicated as a b
cell mitogen in the first place? Melton
and colleagues used a potent antagonist
of the insulin receptor developed at
Novo Nordisk termed S961 (Scha¨ffer
et al., 2008) to acutely cause insulin resis-
tance and increase plasma glucose levels
to induce b cell replication (Yi et al., 2013).
It had been known for decades that insulin
resistance causes b cell mass expansion
in rodents, as seen, for instance, in mice
with genetic inhibition of peripheral insulin
signaling in the liver (Michael et al., 2000;
Withers et al., 1998). The existence of a
circulating factor mediating mitogenic ef-
fects on b cells had been proposed by
others based on increased b cell replica-
tion in islets grafted under the kidney
capsule of insulin-resistant mice (Flier
et al., 2001). Thus, the finding that S961
also causes cell-cycle entry of b cells by932 Cell Metabolism 20, December 2, 2014 ªitself was not surprising. Nonetheless,
the insulin receptor antagonist was estab-
lished in this study as a powerful tool with
which to search for any possible down-
stream b cell mitogen.
In order to identify such a circulating
factor originating from the liver of insulin-
resistant mice, Melton and coworkers
performed expression profiling on the
livers of S961-treated mice to identify po-
tential secreted proteins that might
mediate themitogenic effects. They found
steady-state mRNA levels of ANGPTL8
increased by approximately 4-fold.
ANGPTL8, being a secreted protein,
made an excellent candidate as mediator
linking hepatic insulin resistance to b cell
replication. Yi and colleagues then pro-
ceeded to overexpress ANGPTL8 in the
liver of mice via tail-vein hydrodynamic
plasmid injection and reported an aston-
ishing 17-fold increase in b cell replication
rate, leading within a few days to
increased b cell mass (Yi et al., 2013). In
light of these exciting results, the authors
renamed ANGPTL8 ‘‘betatrophin,’’ befit-
ting its proposed function.
Missing from this initial publication was
the genetic proof that loss of ANGPTL8/
betatrophin would in fact attenuate or pre-
vent b cell mass expansion in any insulin-
resistant setting, or, alternatively, hints on
the molecular mechanism of action, in
particular given that application of
betatrophin to cultured islets did not
trigger replication. This level of support
for any conclusion is frequently required
for high-impact publication of mouse
mechanistic studies and has proven
to be the Achilles’ heel of the initial
optimistic report. Just months after Yi
et al. published their findings, Wang
and colleagues reported that mice null
for ANGPTL8/betatrophin had entirely2014 Elsevier Inc.normal glucose metabolism, even when
made insulin resistant, an effect that re-
quires expansion of b cell mass (Wang
et al., 2013). In a more recent issue of
Cell, Gusarova and colleagues went
even further, showing that neither genetic
ablation of ANGPTL8 nor its overexpres-
sion affect b cell mass in mice (Gusarova
et al., 2014). They also repeated
ANGPTL8 overexpression studies, again
using hydrodynamic delivery of plasmids
via the tail vein, and showed that while
this manipulation is sufficient to increase
plasma triglyceride levels, a known effect
of ANGPTL8 on lipid metabolism, there
was no change in b cell mass. Perhaps
most strikingly, when Gusarova and col-
leagues treated ANGPTL8 mutant mice
with the insulin receptor antagonist
S961, b cell mass was expanded to the
same degree as in control mice, demon-
strating that ANGPTL8 is not required to
mediate the effect of insulin resistance
on b cells in mice. In a Correspondence
piece in the same issue of Cell, the au-
thors of the original betatrophin paper
confirmed that their own null mouse
model was similarly unaffected in terms
of b cell mass expansion in the setting of
insulin resistance (Yi et al., 2014). They
also report that the discrepancy with their
2013 paper appears to have been caused
by high variability of the procedure em-
ployed to increase ANGPTL8 expression
in the liver, which caused a small number
of mice to respond strongly, but many not
at all (Yi et al., 2014).
What are the lessons learned from be-
tatrophin? An important question appears
to be whether rodents are in fact the best
model system to identify b cell mitogens
that might be effective in increasing b
cell mass in type 2 diabetics. Indeed,
pancreatectomy leads to diabetes, but
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humans (Menge et al., 2008), and our
group recently showed that whatever the
stimulus for b cell replication in mice
treated with S961, it had no effect on
transplanted human b cells (Jiao et al.,
2014). Perhaps human b cells are less
responsive to the insulin-resistant state
and need additional ‘‘prodding’’ to re-
enter the cell cycle, such as, for instance,
through suppression of cell-cycle inhibi-
tors (Avrahami et al., 2014). What is clear
from the betatrophin saga is that the prob-
lem of increasing b cell replication and
mass is complicated. Referees and edi-
tors must weigh the excitement of a new
finding versus the level of proof required
to make it public. While the scientific en-
terprise is benefitted by enthusiasm in
the lay public, we must also weigh thenegative consequences of not being
able to keep promises of widely publi-
cized discoveries.REFERENCES
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Brain glucosensing neurons monitor extracellular glucose concentrations and act to defend normoglycemia.
To date, the majority of these neurons have been ascribed to hypothalamic and hindbrain centers. In this
issue, Garfield and colleagues (2014) demonstrate that cholecystokinin-expressing neurons in the rodent
parabrachial nucleus function as glucosensors that counter-regulate hypoglycemia.The parabrachial nucleus (PBN) is a
dorsolateral pontine structure located
around the superior cerebellar peduncle
comprising a diverse population of genet-
ically defined neurons. PBN contains two
main subdivisions, named according
to where they stand in relation to the
peduncle: the medial and lateral PBN
(LPBN). LPBN has been associated with
appetite suppression, as it mediates the
anorectic actions of a number of gut hor-
mones (Becskei et al., 2007). Recently,
the LPBN has been more specifically
linked to a ‘‘permissive’’ role in food
intake. In fact, a distinct subpopulation
of LPBN cells located in its outer external
subdivision, namely the calcitonin gene-related peptide-expressing (CGRPLPBN)
neurons, have been described as medi-
ating appetite suppression in conditions
when it is unfavorable to eat (such as dur-
ing bacterial infections or visceral malaise
[Carter et al., 2013]).
Notwithstanding its critical role in food
intake, the glucosensing and counter-
regulatory functions of LPBN remained
largely unsuspected. In this issue, Gar-
field and colleagues (2014) show that a
distinct subpopulation of LPBN neurons
expressing the peptide cholecystokinin
(CCKLPBN) constitutes an unanticipated
group of glucosensing counter-regulatory
cells. Garfield et al. (2014) first demon-
strated using whole-cell recordings thatdownward shifts in extracellular glucose
resulted in reversible membrane depolar-
ization in approximately 50% of CCKLPBN
neurons tested. The authors then aimed
at observing the effects of silencing
CCKLPBN neurons in vivo. Using Cre-
dependent viral expression of DREADDs
(designer receptors exclusively activated
by designer drugs), Garfield et al. (2014)
selectively suppressed the activity of
CCKLPBN neurons in a cell-specific
manner. They observed that CCKLPBN
neuronal silencing upon administering
the designer drug impaired counter-
regulatory responses to glucoprivation
in vivo. Conversely, DREADD-mediated
excitation of CCKLPBN neurons inducedDecember 2, 2014 ª2014 Elsevier Inc. 933
